前列腺特异性抗原在前列腺癌诊治中的变化和意义

探讨前列腺特异性抗原（PSA）在前列腺癌诊治中的变化及意义。采用双抗体放射免疫分析法测定78例前列腺良、恶性病变患者血清PSA含量，观察31例前列腺癌患者内分泌治疗后PSA变化。结果：前列腺癌组与前列腺增生症组比较，血清PSA差异有极显著性意义（P＜0．01）。前列腺癌临床各期两两比较，血清PSA有极显著性差异（P＜0．01）或显著性差异（P＜0．05）。各组分化程度不同的前列腺癌相比较，血清PSA均无显著性差异（P＞0．05）。前列腺癌患者中核素骨扫描提示癌骨转移与未提示骨转移两组血清PSA比较有极显著性差异（P＜0．01）。血清PSA明显异常可以预测骨转移的概率．血清PSA的动态变化与临床病情演变基本一致。结论：采用双抗体放射免疫分析法进行血清PSA测定在前列腺癌诊治中是一个较敏感而有价值的指标。血清PSA检测与核素骨扫描联合应用对于前列腺癌的诊断以及了解疾病演进会有很大的帮助。

CHANGES AND SIGNIFICANCES OF PROSTATE-SPECIFIC ANTIGEN IN THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER

PURPOSE To study the serum levels of prostate-specific antigen (PSA) in pasients with prostate cancer in order to evaluate its significances in the applications of clinical use.METHODS Serum levels of PSA in 78 patients with benign or malignant prostatic diseases are measured using double antibody radioimmunal analysis. The changes of PSA level in 31 prostate cancer patients before and after endocrine treatment are observed and evaluated.RESULTS Serum levels of PSA in prostate cancer group is higher than those in BPH group (P < 0.01 ). Dif ferent clinical stages have different PSA levels (P<0.01), but not the same for different pathological differentiations (P > 0.05 ). Endocrine treatment can decrease patient's PSA level. CONCLUSIONS PSA is a forensic tumor marker for prostate cancer. It is useful for early diagnosis, sta-ging and monitoring therapeutic effects.